<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04495504</url>
  </required_header>
  <id_info>
    <org_study_id>Pré-BLS-Sterno-RBHP 2018 ELJEZ</org_study_id>
    <nct_id>NCT04495504</nct_id>
  </id_info>
  <brief_title>Administration of Ropivacaine by Bi-laterosternal Multiperforated Catheters Placed Before a Sternotomy for Cardiac Surgery</brief_title>
  <acronym>Pre-BLS-Sterno</acronym>
  <official_title>The Effect of Continuous Administration of Ropivacaine by Bi-laterosternal Multiperforated Catheters Placed Before a Sternotomy for Cardiac Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Clermont-Ferrand</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Clermont-Ferrand</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The sternotomy site is the most painful site after cardiac surgery. Local infiltration of&#xD;
      ropivacaine through the multihole catheters in the bilaterosternal position (BLS) after&#xD;
      sternotomy significantly reduces pain at rest and during mobilization, reduces opioids&#xD;
      consumption, decreases postoperative complications, improves patient comfort and satisfaction&#xD;
      and reduced hospital costs. In this study our hypothesis is to test the efficacity of local&#xD;
      anesthetic administration via the catheters in the BLS position placed before the surgical&#xD;
      incision.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Goal of the study: Evaluation of the effectiveness of BLS technique on a composite endpoint&#xD;
      (pain at rest, pain during patient mobilization and opioid consumption).&#xD;
&#xD;
      Open trial, therapeutic, prospective, monocentric. One group of patients who will benefits&#xD;
      from the placement of two multihole catheters in BLS position:&#xD;
&#xD;
        -  The ropivacaine group (40 patients): placement by the surgeon of two catheters in BLS&#xD;
           position before the surgical incision. Administration of a bolus dose of 10 ml of&#xD;
           ropivacaine 7, 5 mg/mL in each catheter followed by a continuous infusion of ropivacaine&#xD;
           2 mg/ml in a rate of 3 mL/h during the first 48 hours postoperatively.&#xD;
&#xD;
        -  The control group (80 patients) from the two previous studies who underwent standard&#xD;
           analgesia with PCA morphine.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 22, 2020</start_date>
  <completion_date type="Anticipated">April 22, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 22, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Placement by the surgeon of two catheters in BLS position before the surgical incision. Administration of a bolus dose of 10 ml of ropivacaine 7, 5 mg/mL in each catheter followed by a continuous infusion of ropivacaine 2 mg/ml in a rate of 3 mL/h during the first 48 hours postoperatively.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain evaluation</measure>
    <time_frame>Day 2 postoperatively.</time_frame>
    <description>The technique is considered as a fail if : pain rest &gt; 3.5 /10 (0 = no pain; 10 maximum pain) or pain during mobilization &gt; 3.5/10 (0 = no pain; 10 maximum pain)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Opioid consumption</measure>
    <time_frame>Day 2 postoperatively.</time_frame>
    <description>The technique is considered as a fail if morphine consumption &gt; 35 mg</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ICU length of stay</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Days of ICU and hospital stay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital length of stay</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Days of ICU and hospital stay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient satisfaction</measure>
    <time_frame>Day 2 postoperatively.</time_frame>
    <description>Patient satisfaction evaluation from the patient based on a simple Likert scale:&#xD;
0 = very bad; 1 = bad; 2 = medium; 3 = good; 4 = excellent.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative nausea and vomiting</measure>
    <time_frame>Day 1 and 2 postoperatively.</time_frame>
    <description>assessed by the Wengritzky intensity scale (if total score &gt; 50, the nausea and vomiting are clincally significant)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Respiratory complications</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Occurrence of postoperative respiratory complications</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac complications</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Occurrence of postoperative cardiac complications</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neurological complications</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Occurrence of postoperative neurological complications</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal,complications</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Occurrence of postoperative renal complications</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infectious complications</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Occurrence of postoperative infectious complications</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chronic pain evaluation</measure>
    <time_frame>Assessed at the 6th postoperative month</time_frame>
    <description>Chronic pain assessed at the 6th postoperative month by DN4 (Neuropathic Pain Diagnostic 4) score</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Scheduled Cardiac Surgery</condition>
  <condition>Age Under 85 Years</condition>
  <arm_group>
    <arm_group_label>Ropivacaine group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administration of a bolus dose of ropivacaine, followed by a continuous infusion of ropivacaine during the first 48 hours postoperatively.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ropivacaine</intervention_name>
    <description>Administration of a bolus dose of 10 ml of ropivacaine 7, 5 mg/mL in each catheter Continuous infusion of ropivacaine 2 mg/ml in a rate of 3 mL/h during the first 48 hours postoperatively.</description>
    <arm_group_label>Ropivacaine group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients who undergo scheduled cardiac surgery with sternotomy: aortic or mitral valve&#xD;
             replacement, biological or mechanical, coronary bypass surgery&#xD;
&#xD;
          -  Age under 85 years&#xD;
&#xD;
          -  Patients who have given their consent according to the methods described in Title II&#xD;
             of the book of the first Public Health Code&#xD;
&#xD;
          -  Possession of Social Security insurance.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Emergency surgery&#xD;
&#xD;
          -  Approach by thoracotomy&#xD;
&#xD;
          -  Heart transplant&#xD;
&#xD;
          -  Aortic dissection&#xD;
&#xD;
          -  Redo surgery.&#xD;
&#xD;
          -  Pregnant women&#xD;
&#xD;
          -  Refusal of the protocol&#xD;
&#xD;
          -  Protected minors or adults&#xD;
&#xD;
          -  Pre-existing psychiatric pathology including known states of opioid addiction&#xD;
&#xD;
          -  Long-term opioid medication&#xD;
&#xD;
          -  Physical or intellectual inability to use a PCA&#xD;
&#xD;
          -  Severe heart failure (ejection fraction less than 40% or PAH &gt; 50 mmHg)&#xD;
&#xD;
          -  Preoperative cardiogenic shock&#xD;
&#xD;
          -  Severe preoperative chronic or acute renal failure with a creatinine clearance of less&#xD;
             than 30 mL / min according to Cockroft's formula&#xD;
&#xD;
          -  Known hypersensitivity to local anesthetics or to any component of the catheter&#xD;
&#xD;
          -  Known allergy or hypersensitivity to any of the study drugs or analgesia protocol&#xD;
             (ropivacaine, paracetamol, opiates).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vedat Eljezi, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pôle Anesthésie Réanimation / Service de Chirurgie Cardio-Vasculaire</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lise Laclautre</last_name>
    <phone>33 4 73 754 963</phone>
    <email>promo_interne_drci@chu-clermontferrand.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>DRCI CHU Clermont-Ferrand</last_name>
    <phone>04.73.751.195</phone>
    <email>promo_interne_drci@chu-clermontferrand.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU Clermont-Ferrand - Service de Chirurgie Cardio-Vasculaire</name>
      <address>
        <city>Clermont-Ferrand</city>
        <state>Puy De Dôme</state>
        <zip>63000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vedat Eljezi, Dr</last_name>
      <email>veljezi@chu-clermontferrand.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>July 23, 2020</study_first_submitted>
  <study_first_submitted_qc>July 28, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 3, 2020</study_first_posted>
  <last_update_submitted>August 24, 2021</last_update_submitted>
  <last_update_submitted_qc>August 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Postoperative analgesia</keyword>
  <keyword>Sternotomy</keyword>
  <keyword>Local anesthetics</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ropivacaine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

